Table 1.
Impact of patient leader genotype on outcome in HLA-A–, HLA-C–, HLA-DRB1–, or HLA-DQB1–mismatched transplants
| Patient leader genotype | Mortality (n = 10 415) | Nonrelapse mortality (n = 8506) | Disease-free survival (n = 9205) | Relapse (n = 6678) | Chronic GVHD (n = 6707) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/N* | HR | 95% CI; P | n/N* | HR | 95% CI; P | n/N* | HR | 95% CI; P | n/N* | HR | 95% CI; P | n/N* | OR | 95% CI; P | |
| TT | 3324/5802 | 1.0 | — | 1312/4790 | 1.0 | — | 3523/5140 | 1.0 | — | 1199/3781 | 1.0 | — | 1629/3715 | 1.0 | — |
| MT | 2401/3970 | 1.05 | 0.99-1.11; .09 | 897/3211 | 1.03 | 0.94-1.13; .56 | 2538/3502 | 1.07 | 1.02-1.14; .01 | 882/2512 | 1.05 | 0.95-1.15; .36 | 1181/2588 | 1.06 | 0.98-1.16; .14 |
| MM | 406/643 | 1.12 | 1.00-1.25; .05 | 143/505 | 1.08 | 0.89-1.30; .42 | 432/ 563 | 1.18 | 1.05-1.32; .004 | 151/385 | 1.21 | 1.00-1.45; .05 | 184/404 | 1.19 | 1.00-1.41; .04 |
The risks of mortality, nonrelapse mortality, relapse, and chronic GVHD associated with MT and MM HLA-B patient leader genotype relative to TT leader genotype are defined among HLA-A–, HLA-C–, HLA-DRB1–, or HLA-DQB1–mismatched unrelated donor transplants combined as a group. Models adjusted for year of transplant, preparative regimen, disease status, cytomegalovirus serostatus, donor age, stem cell source, donor sex, patient sex, use of total body irradiation, use of T-cell depletion, HLA-DPB1 mismatch status, patient race, donor race, mean HLA-C expression, mean HLA-A expression, mismatched HLA locus, patient HLA-E genotype, and donor killer immunoglobulin-like receptor genotype.
Numbers are provided for patients who developed outcome from the total number of evaluable patients.